Myasthenia gravis treatment aims to minimize the effects of muscle weakness due to an immune process. It includes medications ...
Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback